A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma (NCT06604715)
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D\[s\]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with multiple myeloma (MM) whose disease has come back after treatment (relapsed) or hasn't responded to treatment (refractory).
Who can join: Review the eligibility criteria below.
Location: Princess Margaret Hospital — Toronto, Ontario
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Princess Margaret Hospital — Toronto, Ontario
- Jewish General Hospital — Montreal, Quebec
- Seoul National University Hospital — Seoul,
- Asan Medical Center — Seoul,
- Samsung Medical Center — Seoul,
- The Catholic University of Korea Seoul St Marys Hospital — Seoul,
- Hosp. Univ. Germans Trias I Pujol — Badalona,
- Hosp Clinic de Barcelona — Barcelona,
- Hosp Univ Fund Jimenez Diaz — Madrid,
- Clinica Univ. de Navarra — Pamplona,
- Hosp Clinico Univ de Salamanca — Salamanca,
- Kaohsiung Chang Gung Memorial Hospital — Kaohsiung City,
- China Medical University Hospital — Taichung,
- National Cheng Kung University Hospital — Tainan,
- National Taiwan University Hospital — Taipei,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed or Refractory Multiple Myeloma
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) — Mobile, Alabama
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma — Anchorage, Alaska
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma — Tucson, Arizona
- A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
- A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Relapsed or Refractory Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.